Among the group’s current objectives is the analysis of the role of ADAM and ADAMTS metalloproteinases in tumour progression, and the detection of new cell surface markers in glioblastoma-initiating cells. The implementation of new methodologies for quantitative proteomic analyses, such as iTRAQ and strategies without markers, while continuing to provide services in the most recent proteomic methodologies to other research groups. Visit the research group’s page Centres General Hospital Vall d'Hebron Institute of Oncology Serveis Medical Oncology Ponderació 9 Recerca Grup de Proteòmica Enllaç https://vhio.net/pf/proteomics-group/